GLP-1 costs put strain on public employers |
| The Wall Street Journal looks at how cities, towns and public employers are struggling with surging healthcare costs linked partly to GLP-1 weight-loss drugs such as Ozempic and Wegovy. Belchertown, Massachusetts, received a surprise $911,000 invoice after its insurance trust neared insolvency, forcing savings withdrawals and departmental cuts. Lesa Lessard Pearson, chair of the Select Board, said the reaction was “shock” and “it felt like a betrayal”. Some localities are cutting or limiting coverage, while unions and employees argue the drugs are unaffordable without insurance. Officials are weighing short-term budget damage against possible long-term health benefits, with economists still debating whether savings will materialise. |
|